Aldose reductase inhibitor

From WikiMD.com - Food, Medicine & Wellness Encyclopedia

Aldose Reductase Inhibitor[edit | edit source]

Aldose reductase inhibitors (ARIs) are a class of drugs that inhibit the enzyme aldose reductase, which is involved in the polyol pathway. This pathway is implicated in the development of various complications of diabetes mellitus, such as diabetic neuropathy, retinopathy, and nephropathy. By inhibiting aldose reductase, these drugs aim to prevent or ameliorate these complications.

Mechanism of Action[edit | edit source]

Aldose reductase is an enzyme that catalyzes the reduction of glucose to sorbitol, a sugar alcohol, in the polyol pathway. Under normal conditions, this pathway is responsible for a small fraction of glucose metabolism. However, in hyperglycemic states, such as in diabetes, the flux through this pathway increases, leading to the accumulation of sorbitol and fructose. This accumulation can cause osmotic and oxidative stress, contributing to cellular damage.

ARIs work by inhibiting aldose reductase, thereby reducing the conversion of glucose to sorbitol. This helps to prevent the osmotic and oxidative stress that can lead to tissue damage in diabetic complications.

Clinical Applications[edit | edit source]

ARIs have been investigated for their potential to treat and prevent complications of diabetes, including:

  • Diabetic Neuropathy: ARIs may help in reducing nerve damage and alleviating symptoms such as pain and numbness.
  • Diabetic Retinopathy: By reducing sorbitol accumulation in the retina, ARIs may help in preventing or slowing the progression of retinopathy.
  • Diabetic Nephropathy: ARIs may protect kidney function by preventing sorbitol-induced damage to renal cells.

Examples of Aldose Reductase Inhibitors[edit | edit source]

Several ARIs have been developed and studied, including:

  • Alrestatin: One of the first ARIs developed, but not widely used due to limited efficacy and side effects.
  • Epalrestat: The only ARI approved for clinical use in some countries, particularly in Japan, for the treatment of diabetic neuropathy.
  • Fidarestat: An investigational ARI with potential benefits in diabetic complications.
  • Imirestat: Another investigational ARI.
  • Lidorestat: An ARI under investigation for its effects on diabetic complications.
  • Minalrestat: An investigational ARI.
  • Ponalrestat: An ARI that was studied but not widely adopted.
  • Ranirestat: An investigational ARI with potential benefits in diabetic neuropathy.
  • Salfredin B11: A natural product with aldose reductase inhibitory activity.
  • Sorbinil: An early ARI that showed promise but was associated with adverse effects.
  • Tolrestat: An ARI that was withdrawn from the market due to safety concerns.

Challenges and Limitations[edit | edit source]

Despite the potential benefits of ARIs, their clinical use has been limited by several factors:

  • Efficacy: Many ARIs have shown limited efficacy in clinical trials.
  • Safety: Some ARIs have been associated with adverse effects, leading to their withdrawal from the market.
  • Pharmacokinetics: The pharmacokinetic properties of some ARIs have limited their effectiveness.

Future Directions[edit | edit source]

Research continues to develop more effective and safer ARIs. Advances in understanding the structure and function of aldose reductase may lead to the development of more selective inhibitors with better clinical profiles.

Related Pages[edit | edit source]

Gallery[edit | edit source]

Aldose_reductase_inhibitor[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Transform your life with W8MD's budget GLP1 injections from $125

W8mdlogo.png
W8MD weight loss doctors team

W8MD offers a medical weight loss program NYC and a clinic to lose weight in Philadelphia. Our W8MD's physician supervised medical weight loss centers in NYC provides expert medical guidance, and offers telemedicine options for convenience.

Why choose W8MD?

Book Your Appointment

Start your NYC weight loss journey today at our NYC medical weight loss, and Philadelphia medical weight loss Call (718)946-5500 for NY and 215 676 2334 for PA

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's NYC physician weight loss.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available. Call 718 946 5500.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD